Eric Pasmant

List of Publications by Year
in descending order

97 papers	4,871 citations	126907 33 h-index	98798 67 g-index
101 all docs	101 docs citations	101 times ranked	8265 citing authors

#	Article	IF	Citations
1	Characterization of a Germ-Line Deletion, Including the Entire INK4/ARF Locus, in a Melanoma-Neural System Tumor Family: Identification of ANRIL, an Antisense Noncoding RNA Whose Expression Coclusters with ARF. Cancer Research, 2007, 67, 3963-3969.	0.9	582
2	ANRIL , a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB Journal, 2011, 25, 444-448.	0.5	413
3	PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature, 2014, 514, 247-251.	27.8	386
4	COVID-19: Discovery, diagnostics and drug development. Journal of Hepatology, 2021, 74, 168-184.	3.7	302
5	Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype phenotype relationships and overlap with Costello syndrome. Journal of Medical Genetics, 2007, 44, 763-771.	3.2	221
6	NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Human Mutation, 2010, 31, E1506-E1518.	2.5	208
7	NF1 Molecular Characterization and Neurofibromatosis Type I Genotype-Phenotype Correlation: The French Experience. Human Mutation, 2013, 34, 1510-1518.	2.5	140
8	Neurofibromatosis type 1: from genotype to phenotype. Journal of Medical Genetics, 2012, 49, 483-489.	3.2	133
9	Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Human Molecular Genetics, 2009, 18, 2768-2778.	2.9	129
10	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics, 2012, 21, 5397-5405.	2.9	126
11	RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget, 2016, 7, 38892-38907.	1.8	116
12	Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. Journal of the National Cancer Institute, 2011, 103, 1713-1722.	6.3	106
13	BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nature Communications, 2019, 10, 348.	12.8	105
14	SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. Journal of Medical Genetics, 2009, 46, 425-430.	3.2	103
15	Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?. European Journal of Human Genetics, 2015, 23, 596-601.	2.8	97
16	Mutations inSETD2cause a novel overgrowth condition. Journal of Medical Genetics, 2014, 51, 512-517.	3.2	96
17	Expression of ANRILâ€“Polycomb Complexesâ€“CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value. Molecular Cancer Research, 2016, 14, 623-633.	3.4	84
18	Review and update ofSPRED1mutations causing legius syndrome. Human Mutation, 2012, 33, 1538-1546.	2.5	81

#	Article	IF	Citations
19	Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes and Development, 2015, 29, 2547-2562.	5.9	77
20	Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. British Journal of Cancer, 2016, 114, 1395-1404.	6.4	75
21	Chaperoning 5S RNA assembly. Genes and Development, 2015, 29, 1432-1446.	5.9	54
22	SETD2andDNMT3Ascreen in the Sotos-like syndrome French cohort. Journal of Medical Genetics, 2016, 53, 743-751.	3.2	54
23	Confirmation of mutation landscape of NF1â€associated malignant peripheral nerve sheath tumors. Genes Chromosomes and Cancer, 2017, 56, 421-426.	2.8	54
24	Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro-Oncology, 2018, 20, 917-929.	1.2	48
25	SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. Oncogene, 2015, 34, 631-638.	5.9	47
26	Identification of Genes Potentially Involved in the Increased Risk of Malignancy in NF1-Microdeleted Patients. Molecular Medicine, 2011, 17, 79-87.	4.4	46
27	MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics, 2013, 14, 473.	2.8	46
28	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget, 2016, 7, 35753-35767.	1.8	46
29	The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis. Clinical Cancer Research, 2014, 20, 358-371.	7.0	44
30	First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis. European Journal of Human Genetics, 2012, 20, 277-282.	2.8	42
31	EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6075-6080.	7.1	42
32	SPRED1 disorder and predisposition to leukemia in children. Blood, 2009, 114, 1131-1131.	1.4	40
33	UMD-MEN1 Database: An Overview of the 370 MEN1 Variants Present in 1676 Patients From the French Population. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 753-764.	3.6	39
34	Identification by FFPE RNAâ€Seq of a new recurrent inversion leading to RBM10â€TFE3 fusion in renal cell carcinoma with subtle TFE3 breakâ€apart FISH pattern. Genes Chromosomes and Cancer, 2016, 55, 541-548.	2.8	32
35	Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH. Journal of Molecular Diagnostics, 2009, 11, 524-529.	2.8	31
36	Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes. British Journal of Ophthalmology, 2015, 99, 437-439.	3.9	31

#	Article	IF	Citations
37	Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient. European Journal of Human Genetics, 2008, 16, 1459-1466.	2.8	30
38	Unraveling the intrafamilial correlations and heritability of tumor types in MEN1: a Groupe d'Ã©tude des Tumeurs Endocrines study. European Journal of Endocrinology, 2015, 173, 819-826.	3.7	29
39	Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3NF1deletions. Human Mutation, 2012, 33, 372-383.	2.5	28
40	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discovery, 2022, 12, 1435-1448.	9.4	28
41	Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1319-E1328.	7.1	27
42	KDM1A inactivation causes hereditary food-dependent Cushing syndrome. Genetics in Medicine, 2022, 24, 374-383.	2.4	27
43	Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. Endocrine-Related Cancer, 2018, 25, L13-L17.	3.1	22
44	High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRILâ€“ARF Bidirectional Promoter. Non-coding RNA, 2019, 5, 44.	2.6	21
45	Proposition of adjustments to the ACMGâ€AMP framework for the interpretation of MEN1 missense variants. Human Mutation, 2019, 40, 661-674.	2.5	21
46	Humanized Mouse Model to Study Type 1 Diabetes. Diabetes, 2018, 67, 1816-1829.	0.6	20
47	Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. Thyroid, 2022, 32, 594-598.	4.5	19
48	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib. Cancer Immunology Research, 2017, 5, 582-593.	3.4	17
49	Differential Expression ofCCN1/CYR61,CCN3/NOV,CCN4/WISP1, andCCN5/WISP2in Neurofibromatosis Type 1 Tumorigenesis. Journal of Neuropathology and Experimental Neurology, 2010, 69, 60-69.	1.7	16
50	Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. Journal of Medical Genetics, 2020, 57, 104-108.	3.2	16
51	NF1 single and multi-exons copy number variations in neurofibromatosis type 1. Journal of Human Genetics, 2015, 60, 221-224.	2.3	15
52	Severe Phenotype in Patients with Large Deletions of NF1. Cancers, 2021, 13, 2963.	3.7	15
53	NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas. Cancer Medicine, 2019, 8, 4330-4337.	2.8	14
54	Identification ofTP53mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments. International Journal of Gynecological Cancer, 2020, 30, 640-647.	2.5	13

#	Article	IF	Citations
55	Should we genotype the sperm of fathers from patients with â€˜de novoâ€™ mutations?. European Journal of Endocrinology, 2020, 182, C1-C3.	3.7	13
56	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	7.2	12
57	BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis. , 2020, 8, e000275.		11
58	The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas. PLoS ONE, 2019, 14, e0214416.	2.5	10
59	Different sized somatic NF1 locus rearrangements in neurofibromatosisÂ1-associated malignant peripheral nerve sheath tumors. Journal of Neuro-Oncology, 2011, 102, 341-346.	2.9	9
60	Familial small-intestine carcinoids: Chromosomal alterations and germline inositol polyphosphate multikinase sequencing. Digestive and Liver Disease, 2017, 49, 98-102.	0.9	9
61	VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis. Thrombosis Research, 2010, 126, e134-e136.	1.7	8
62	Immunohistochemistry versus next-generation sequencing for the routine detection of BRAF V600E mutation in melanomas. Human Pathology, 2014, 45, 1983-1984.	2.0	8
63	Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities. Orphanet Journal of Rare Diseases, 2016, 11, 101.	2.7	7
64	Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing. Journal of Molecular Diagnostics, 2017, 19, 776-787.	2.8	7
65	Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression. Journal of Biological Chemistry, 2019, 294, 12992-13005.	3.4	7
66	McCune Albright syndrome is a genetic predisposition to intraductal papillary and mucinous neoplasms of the pancreas associated pancreatic cancer in relation with GNAS somatic mutation â€“ a case report. Medicine (United States), 2019, 98, e18102.	1.0	7
67	A severe neonatal presentation of factor II deficiency. European Journal of Haematology, 2011, 87, 464-466.	2.2	6
68	High specificity and sensitivity of NRAS Q61R immunohistochemistry (IHC) in melanomas. Journal of the American Academy of Dermatology, 2016, 74, 572-573.	1.2	6
69	Neurofibromatosis type 2 French cohort analysis using a comprehensive NF2 molecular diagnostic strategy. Neurochirurgie, 2018, 64, 335-341.	1.2	6
70	Proteome analysis of formalinâ€fixed paraffinâ€embedded colorectal adenomas reveals the heterogeneous nature of traditional serrated adenomas compared to other colorectal adenomas. Journal of Pathology, 2020, 250, 251-261.	4.5	6
71	Relevance of MPNST cell lines as models for NF1 associated-tumors. Journal of Neuro-Oncology, 2013, 114, 353-355.	2.9	5
72	Synovial Sarcomas Do Not Show H3K27 Trimethylation Loss Using Immunohistochemistry. American Journal of Surgical Pathology, 2017, 41, 283-285.	3.7	5

#	Article	IF	Citations
73	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. American Journal of the Medical Sciences, 2018, 356, 404-407.	1.1	5
74	One NF1 Mutation may Conceal Another. Genes, 2019, 10, 633.	2.4	5
75	Natural history of NF1 c.2970_2972del p.(Met992del): confirmation of a low risk of complications in a longitudinal study. European Journal of Human Genetics, 2022, 30, 291-297.	2.8	5
76	Unraveling the genetic predisposition of ribavirin-induced anaemia. Journal of Hepatology, 2010, 53, 971-973.	3.7	4
77	Two independent de novo mutations as a cause for neurofibromatosis type 1 and Noonan syndrome in a single family. American Journal of Medical Genetics, Part A, 2012, 158A, 2290-2291.	1.2	4
78	NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation. Neuro-Oncology Advances, 2020, 2, i98-i106.	0.7	4
79	RAS MAPK inhibitors deregulation in leukemia. Oncoscience, 2015, 2, 930-931.	2.2	4
80	A natural variant with a point mutation resulting in a homozygous Arg to His substitution at position 388 in prothrombin. Haematologica, 2008, 93, 799-800.	3.5	3
81	Neurofibromatosis Type 1 Molecular Diagnosis: The RNA Point of View. EBioMedicine, 2016, 7, 21-22.	6.1	3
82	Prenatal features and neonatal management of severe hyperparathyroidism caused by the heterozygous inactivating calcium-sensing receptor variant, Arg185Gln: A case report and review of the literature. Bone Reports, 2021, 15, 101097.	0.4	3
83	Abstract PR15: SUZ12: A novel tumor suppressor and potential biomarker for efficacy of BRD4 inhibition. Cancer Research, 2013, 73, PR15-PR15.	0.9	2
84	Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. European Journal of Endocrinology, 2022, 186, 607-617.	3.7	2
85	VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop. Annals of Diagnostic Pathology, 2022, 60, 151997.	1.3	2
86	Modifier Genes in NF1. , 2012, , 269-285.		1
87	â€œMPNST Epigeneticsâ€â€”Letter. Molecular Cancer Research, 2019, 17, 2139-2139.	3.4	1
88	Noninvasive Prenatal Diagnosis of a Paternally Inherited MEN1 Pathogenic Splicing Variant. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1367-e1373.	3.6	1
89	PRC2 Subunits Are Tumor Suppressors in NF1-Deficient Solid Tumors. Cancer Discovery, 2014, 4, 1114.2-1114.	9.4	0
90	Primary giant cell tumor of the common bile duct: No mutation H3F3A found. Pathology International, 2017, 67, 225-227.	1.3	0

#	Article	IF	Citations
91	Abstract LB-79: PRC2 loss amplifies Ras-driven transcription and sensitizes cancers to bromodomain inhibitor-based combination therapies. , 2014, , .		0
92	Abstract 5511: Characterization of molecular and functional consequences of somaticNF1mutations in non-small cell lung cancers. , 2018, , .		0
93	Abstract 4609: High-grade TP53-mutated endometrial carcinomas have decreased NRF2 antioxidant activity. , 2018, , .		0
94	Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models. Blood, 2019, 134, 2671-2671.	1.4	0
95	Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. Blood Cells, Molecules, and Diseases, 2021, 92, 102623.	1.4	0
96	Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 739-743.	2.4	0
97	Abstract 4955: Impact of PD-1, PD-L1 and EBI3 on prognosis in a cohort of localized high grade undifferentiated pleomorphic sarcoma patients. , 2019, , .		0